Myeloid leukemia in down syndrome

Irum Khan, Sébastien Malinge, John D. Crispino

Research output: Contribution to journalReview article

62 Scopus citations

Abstract

Although adults with Down syndrome (DS) show a decreased incidence of cancer compared to individuals without DS, children with DS are at an increased risk of leukemia. Nearly half of these childhood leukemias are classified as acute megakaryoblastic leukemia (AMKL), a relatively rare subtype of acute myeloid leukemia (AML). Here, we summarize the clinical features of myeloid leukemia in DS, review recent research on the mechanisms of leukemogenesis, including the roles of GATA1 mutations and trisomy 21, and discuss treatment strategies. Given that trisomy 21 is a relatively common event in hematologic malignancies, greater knowledge of how the genes on chromosome 21 contribute to DS-AMKL will increase our understanding of a broader class of patients with leukemia.

Original languageEnglish (US)
Pages (from-to)25-36
Number of pages12
JournalCritical Reviews in Oncogenesis
Volume16
Issue number1-2
DOIs
StatePublished - Jan 1 2011

Keywords

  • Acute megakaryoblastic leukemia (AMKL)
  • GATA-1
  • Transient myeloproliferative disorder (TMD)
  • Trisomy 21

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Myeloid leukemia in down syndrome'. Together they form a unique fingerprint.

  • Cite this